Abiopharma

🔍 Bausch Shelley J (Executive)

Company: GATX CORP (GATX)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 128 shares of Common Stock at $194.9175 per share (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: false | shares_owned_after: 4,165.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents additional RSUs credited to the reporting person's account under the Amended and Restated GATX Corporation Directors' Voluntary Deferred Fee Plan ("Deferred Fee Plan") credited on the transaction date. Each RSU represents the right to receive one share of Issuer's common stock upon settlement. The RSUs are generally payable on a deferred basis in common stock at the election of the reporting person upon the reporting person's termination of service on the Issuer's board of directors.
• F2: Represents (a) 13 RSUs acquired pursuant to the dividend reinvestment feature of the Deferred Fee Plan, and (b) 115 RSUs acquired under the Deferred Fee Plan resulting from the reporting person's election to defer the annual cash retainer and other cash fees payable to the reporting person in the form of RSUs under the Deferred Fee Plan.